Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE（PATH-STROKE）
Trial Parameters
Brief Summary
1. Main objective: To explore the efficacy of precise antiplatelet therapy guided by platelet aggregation function in reducing the incidence of 30 day platelet hyperresponsiveness in patients with non-cardiogenic ischemic stroke. 2. Secondary objective: To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic ischemic stroke under the guidance of platelet aggregation function.
Eligibility Criteria
Inclusion Criteria: 1. Aged from 18 to 80 years; 2. Diagnosed with non-cardiogenic ischemic stroke according to WHO criteria, confirmed by cranial CT or MRI to exclude hemorrhagic stroke.; 3. First stroke onset ≥ 1 month and ≤ 3 months; 4. mRS Score \<=2 points; 5. Undergoing antiplatelet therapy with 100mg aspirin daily for at least 8 days; 6. Informed consent signed by the patient or their family member. Exclusion Criteria: 1. History of recurrent stroke. 2. History of gastrointestinal bleeding, intracranial hemorrhage, or other bleeding disorders. 3. Contraindications or intolerance to antiplatelet therapy medications. 4. Severe cardiac, pulmonary, hepatic, or renal insufficiency, or presence of severe comorbid conditions (e.g., end-stage malignant tumors, severe single/multiple organ failure). 5. Poor compliance, inability to cooperate with study requirements.